Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palifermin and SSA for Immune Recovery After HSCT
NCT01746849Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2012
- Primary completion
- Dec 2026
- Modality
- Cytokines & Interferons, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of palifermin, leuprolide and degarelix in immunodeficiency, sponsored by Memorial Sloan Kettering Cancer Center. Started Dec 2012; status: active, not recruiting.
02
Drugs
paliferminleuprolidedegarelix
03
Conditions
immunodeficiency
Beyond the preview
Go deeper on NCT01746849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01746849.